Wall Street Zen Upgrades Integra LifeSciences (NASDAQ:IART) to "Buy"

Key Points

• Wall Street Zen upgraded Integra LifeSciences from “hold” to “buy,” even though the broader analyst picture remains cautious with an average rating of “Reduce” and an average target price of $12.75.
• The company reported better-than-expected quarterly results, posting EPS of $0.54 versus $0.41 expected and revenue of $391.92 million versus $381.81 million expected; revenue also rose 2.4% year over year.
• Shares were trading up 2.7% at $13.92, and the stock sits above its 50-day and 200-day moving averages, while institutional investors continue to hold a large stake in the company.

Integra LifeSciences (NASDAQ:IART - Get Free Report) was upgraded by Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued on Saturday.

Several other research analysts also recently issued reports on IART. Wells Fargo & Company lifted their price objective on Integra LifeSciences from $12.00 to $15.00 and gave the stock an "equal weight" rating in a research report on Wednesday. Citigroup lifted their price objective on Integra LifeSciences from $9.00 to $11.00 and gave the stock a "sell" rating in a research report on Wednesday. Weiss Ratings restated a "sell (e+)" rating on shares of Integra LifeSciences in a research report on Friday, March 27th. Argus restated a "hold" rating on shares of Integra LifeSciences in a research report on Wednesday, April 15th. Finally, Truist Financial cut their price objective on Integra LifeSciences from $13.00 to $12.00 and set a "hold" rating for the company in a research report on Wednesday, April 15th. Three equities research analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Reduce" and an average target price of $12.75.

Integra LifeSciences Trading Up 2.7%

Shares of Integra LifeSciences stock opened at $13.92 on Friday. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.38 and a quick ratio of 1.46. Integra LifeSciences has a 1 year low of $8.70 and a 1 year high of $16.49. The company has a market capitalization of $1.08 billion, a P/E ratio of -2.15 and a beta of 1.08. The business has a 50 day moving average price of $10.20 and a 200 day moving average price of $11.71.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The life sciences company reported $0.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.13. Integra LifeSciences had a positive return on equity of 17.42% and a negative net margin of 30.15%.The firm had revenue of $391.92 million during the quarter, compared to the consensus estimate of $381.81 million. During the same period in the previous year, the firm posted $0.41 EPS. The company's quarterly revenue was up 2.4% compared to the same quarter last year. Integra LifeSciences has set its FY 2026 guidance at 2.400-2.500 EPS and its Q2 2026 guidance at 0.440-0.520 EPS. Sell-side analysts anticipate that Integra LifeSciences will post 2.44 EPS for the current fiscal year.

Institutional Trading of Integra LifeSciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. Allianz Asset Management GmbH boosted its holdings in shares of Integra LifeSciences by 88.7% in the 3rd quarter. Allianz Asset Management GmbH now owns 433,738 shares of the life sciences company's stock valued at $6,215,000 after purchasing an additional 203,834 shares during the last quarter. Hussman Strategic Advisors Inc. acquired a new position in shares of Integra LifeSciences in the 3rd quarter valued at $2,407,000. SG Americas Securities LLC acquired a new position in shares of Integra LifeSciences in the 4th quarter valued at $4,722,000. Assenagon Asset Management S.A. boosted its holdings in shares of Integra LifeSciences by 15.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 526,302 shares of the life sciences company's stock valued at $6,537,000 after purchasing an additional 71,950 shares during the last quarter. Finally, SummerHaven Investment Management LLC acquired a new position in shares of Integra LifeSciences in the 3rd quarter valued at $928,000. 84.78% of the stock is owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.